Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]
Endocrine Connections, 2018 Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar +3 more
doaj +5 more sources
Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
Chinese Medical Journal, 2017 Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj +3 more sources
Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo
Journal of the Egyptian Women’s Dermatologic SocietyBackground Programmed cell death 1 (PD-1) is a cell surface protein that serves as an immune checkpoint in conjunction with its two ligands, PD-L1 and PD-L2.
Hanan R. Nada +5 more
doaj +2 more sources
Programmed cell death protein 1 in cancer cells
Cell Communication and SignalingProgrammed cell death protein 1 (PD-1) is frequently detected in certain subsets of tumor cells, and our understanding of PD-1 signaling consequences has expanded to include control of tumor growth, stemness and drug resistance.
Chunlian Wei, Meijun Liu, Weifen Zhang
doaj +3 more sources
Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis [PDF]
Critical Care, 2014 INTRODUCTION: A major pathophysiologic mechanism in sepsis is impaired host immunity which results in failure to eradicate invading pathogens and increased susceptibility to secondary infections.
Andriani C Patera +13 more
core +6 more sources
Fatal adverse events associated with programmed cell death protein 1 or programmed cell death-ligand 1 monotherapy in cancer [PDF]
Therapeutic Advances in Medical Oncology, 2020 Background: The introduction of antibodies targeting programmed cell death protein 1 (PD-1) and programmed cell death-ligand 1 (PD-L1) into clinical practice has had a revolutionary effect on cancer treatment.
Bin Zhao, Hong Zhao, Jiaxin Zhao
doaj +3 more sources
Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]
Critical Care, 2018 Debasree Banerjee +7 more
doaj +3 more sources
Programmed Cell Death-1/Programmed Cell Death Ligand-1 Checkpoint Inhibitors: Differences in Mechanism of Action [PDF]
Immunotherapy, 2019 Programmed cell death-1 (PD-1)/programmed death-ligand 1 (PD-L1) checkpoint inhibitors are widely used in many types of solid tumors, and are often considered to be in the same immunotherapy subclass. This review explores whether specific agents in these two categories exhibit differences in their mechanism of action, pharmacokinetics and ...
Ni, Zhang +3 more
openaire +2 more sources
Polish Journal of Pathology, 2021 Neuroendocrine carcinomas (NECs) of the urinary bladder are rare and aggressive, without an effective treatment approach. Immune checkpoint inhibitor agents targeting the interaction of programmed cell death protein 1 (PD-1) and programmed death ligand 1
Arbil Acikalin +4 more
doaj +1 more source
Anti-programmed cell death protein-1/ligand-1 therapy in different cancers. [PDF]
, 2015 Immunologic checkpoint blockade with antibodies against the programmed cell death protein-1 (PD-1) or its ligand (PD-L1) is an effective method for reversing cancer immunosuppression and thereby promoting immune responses against several cancer types ...
Homet Moreno, B, Ribas, A
core +2 more sources